Stephan R Lindner1,2, Miguel Marino2,3, Jean O'Malley4, Heather Angier3, Steffani R Bailey3, Megan Hoopes4, Rachel Springer3, K John McConnell5,2, Jennifer DeVoe3, Nathalie Huguet3. 1. Center for Health Systems Effectiveness and Department of Emergency Medicine, Oregon Health & Science University, Portland, OR lindners@ohsu.edu. 2. OHSU-PSU School of Public Health, Portland, OR. 3. Department of Family Medicine, Oregon Health & Science University, Portland, OR. 4. OCHIN, Inc., Portland, OR. 5. Center for Health Systems Effectiveness and Department of Emergency Medicine, Oregon Health & Science University, Portland, OR.
Abstract
OBJECTIVE: To compare trends in Medicaid expenditures among adults with diabetes who were newly eligible due to the Affordable Care Act (ACA) Medicaid expansion to trends among those previously eligible. RESEARCH DESIGN AND METHODS: Using Oregon Medicaid administrative data from 1 January 2014 to 30 September 2016, a retrospective cohort study was conducted with propensity score-matched Medicaid eligibility groups (newly and previously eligible). Outcome measures included total per-member per-month (PMPM) Medicaid expenditures and PMPM expenditures in the following 12 categories: inpatient visits, emergency department visits, primary care physician visits, specialist visits, prescription drugs, transportation services, tests, imaging and echography, procedures, durable medical equipment, evaluation and management, and other or unknown services. RESULTS: Total PMPM Medicaid expenditures for newly eligible enrollees with diabetes were initially considerably lower compared with PMPM expenditures for matched previously eligible enrollees during the first postexpansion quarter (mean values $561 vs. $793 PMPM, P = 0.018). Within the first three postexpansion quarters, PMPM expenditures of the newly eligible increased to a similar but slightly lower level. Afterward, PMPM expenditures of both groups continued to increase steadily. Most of the overall PMPM expenditure increase among the newly eligible was due to rapidly increasing prescription drug expenditures. CONCLUSIONS: Newly eligible Medicaid enrollees with diabetes had slightly lower PMPM expenditures than previously eligible Medicaid enrollees. The increase in PMPM prescription drug expenditures suggests greater access to treatment over time.
OBJECTIVE: To compare trends in Medicaid expenditures among adults with diabetes who were newly eligible due to the Affordable Care Act (ACA) Medicaid expansion to trends among those previously eligible. RESEARCH DESIGN AND METHODS: Using Oregon Medicaid administrative data from 1 January 2014 to 30 September 2016, a retrospective cohort study was conducted with propensity score-matched Medicaid eligibility groups (newly and previously eligible). Outcome measures included total per-member per-month (PMPM) Medicaid expenditures and PMPM expenditures in the following 12 categories: inpatient visits, emergency department visits, primary care physician visits, specialist visits, prescription drugs, transportation services, tests, imaging and echography, procedures, durable medical equipment, evaluation and management, and other or unknown services. RESULTS: Total PMPM Medicaid expenditures for newly eligible enrollees with diabetes were initially considerably lower compared with PMPM expenditures for matched previously eligible enrollees during the first postexpansion quarter (mean values $561 vs. $793 PMPM, P = 0.018). Within the first three postexpansion quarters, PMPM expenditures of the newly eligible increased to a similar but slightly lower level. Afterward, PMPM expenditures of both groups continued to increase steadily. Most of the overall PMPM expenditure increase among the newly eligible was due to rapidly increasing prescription drug expenditures. CONCLUSIONS: Newly eligible Medicaid enrollees with diabetes had slightly lower PMPM expenditures than previously eligible Medicaid enrollees. The increase in PMPM prescription drug expenditures suggests greater access to treatment over time.
Authors: Heather Angier; Megan Hoopes; Rachel Gold; Steffani R Bailey; Erika K Cottrell; John Heintzman; Miguel Marino; Jennifer E DeVoe Journal: Ann Fam Med Date: 2015 Jan-Feb Impact factor: 5.166
Authors: Zirui Song; Dana Gelb Safran; Bruce E Landon; Mary Beth Landrum; Yulei He; Robert E Mechanic; Matthew P Day; Michael E Chernew Journal: Health Aff (Millwood) Date: 2012-07-11 Impact factor: 6.301
Authors: Mary E Charlson; Robert E Charlson; Janey C Peterson; Spyridon S Marinopoulos; William M Briggs; James P Hollenberg Journal: J Clin Epidemiol Date: 2008-07-10 Impact factor: 6.437
Authors: Jean P O'Malley; Maureen O'Keeffe-Rosetti; Robert A Lowe; Heather Angier; Rachel Gold; Miguel Marino; Brigit Hatch; Megan Hoopes; Steffani R Bailey; John Heintzman; Charles Gallia; Jennifer E DeVoe Journal: Med Care Date: 2016-11 Impact factor: 2.983
Authors: Jordan Gemelas; Miguel Marino; Steele Valenzuela; Teresa Schmidt; Andrew Suchocki; Nathalie Huguet Journal: BMJ Open Diabetes Res Care Date: 2021-12